FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:430-432 January 25, 2007 Number 4

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Fourth edition. Edited by Noel R. Rose and Ian R. Mackay. 1134 pp., illustrated. San Diego, CA, Elsevier Academic Press, 2006. $199.95. ISBN 978-0-12-595961-2.

The renaissance in the study of regulatory T cells, which began in the mid-1990s, has much improved our understanding of the developmental mechanisms of autoimmune diseases. T-cell–mediated suppression of the immune response was recognized more than three decades ago, but phenotypic characterization of regulatory T cells opened the way for detailed studies of their development and function in inflammatory and autoimmune conditions. Regulatory T cells interfere with the generation of effector T-cell function in vivo. They express the gene coding for transcription factor FOXP3. Studies of the FOXP3 gene in mice have indicated that mutations in this gene impair the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.